The efficacy and tolerance of tocainide used alone and in combination with quinidine were studied in 20 patients with coronary artery disease and frequent (2:::30/h) ventricular premature complexes. Holter electrocardiographic monitoring was performed at baseline and during therapy with tocainide alone, quinidine alone and a combination of tocainide and quinidine. During single drug therapy, the dose of tocainide was 1,680 ± 437 mg/day and that of quinidine was 1,340 ± 235 mg/day. During combination therapy, with smaller doses of tocainide (1,350 ± 394 mg/day) and quinidine (1,060 ± 268 mg/day) in many patients , no patient had side effects. At baseline before therapy, the mean ventricular premature complexeslh were 629 ± 567, couplets/h were 23.9 ± 29.7 and nonsustained ventricular tachycardias/ 24 h were 60.5 ± 152.2. Compared with baseline values (100%), the frequency of ventricular premature complexes was reduced to 33 ± 44% with quinidine, 39 ± 30% with tocainide and 10 ± 16% with combination therapy (p < 0.01 for combination versus quinidine or Tocainide is a lidocaine analogue that is used for long-term oral therapy of ventricular arrhythmia. It has been used in treatment of patients with ventricular premature complexes (1-4) and recurrent sustained ventricular tachycardia (5-8) . Its antiarrhythmic efficacy may be approximately that of other antiarrhythmic agents , such as quinidine , procainamide and disopyramide (9, 10). Its efficacy, like that of other antiarrhythmic agents , is often limited by dose-related side effects (8-10). A significant number of patients develop dose-related side effects when taking tocainide in a dosage that achieves plasma levels adequate for arrhythmia suppression (8). When the dosage of tocainide is reduced to a tolerable level , arrhythmias often recur (8). Because the side Individually, an effective regimen (>83% reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia) was found in 3 (15%) of 20 patients receiving tocainide alone, in 6 (30%) receiving quinidine alone and in 16 (80%) receiving combination therapy (p < 0.01 for tocainide versus combination, quinidine versus combination; p = NS for tocainide versus quinidine).
The efficacy and tolerance of tocainide used alone and in combination with quinidine were studied in 20 patients with coronary artery disease and frequent (2:::30/h) ventricular premature complexes. Holter electrocardiographic monitoring was performed at baseline and during therapy with tocainide alone, quinidine alone and a combination of tocainide and quinidine. During single drug therapy, the dose of tocainide was 1,680 ± 437 mg/day and that of quinidine was 1,340 ± 235 mg/day. During combination therapy, with smaller doses of tocainide (1,350 ± 394 mg/day) and quinidine (1,060 ± 268 mg/day) in many patients , no patient had side effects. At baseline before therapy, the mean ventricular premature complexeslh were 629 ± 567, couplets/h were 23.9 ± 29.7 and nonsustained ventricular tachycardias/ 24 h were 60.5 ± 152.2. Compared with baseline values (100%), the frequency of ventricular premature complexes was reduced to 33 ± 44% with quinidine, 39 ± 30% with tocainide and 10 ± 16% with combination therapy (p < 0.01 for combination versus quinidine or Tocainide is a lidocaine analogue that is used for long-term oral therapy of ventricular arrhythmia. It has been used in treatment of patients with ventricular premature complexes (1-4) and recurrent sustained ventricular tachycardia (5) (6) (7) (8) . Its antiarrhythmic efficacy may be approximately that of other antiarrhythmic agents , such as quinidine , procainamide and disopyramide (9, 10) . Its efficacy, like that of other antiarrhythmic agents , is often limited by dose-related side effects (8) (9) (10) . A significant number of patients develop dose-related side effects when taking tocainide in a dosage that achieves plasma levels adequate for arrhythmia suppression (8) . When the dosage of tocainide is reduced to a tolerable level , arrhythmias often recur (8) . Because the side Individually, an effective regimen (>83% reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia) was found in 3 (15%) of 20 patients receiving tocainide alone, in 6 (30%) receiving quinidine alone and in 16 (80%) receiving combination therapy (p < 0.01 for tocainide versus combination, quinidine versus combination; p = NS for tocainide versus quinidine).
Thus, the antiarrhythmic effects of quinidine and tocainide are additive. A combination of quinidine and tocainide in smaller and well tolerated doses may avoid dose-related side effects and is more effective than either drug used alone at higher doses. Therefore, when quinidine or tocainide is ineffective because dose-related side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses may avoid side effects and may be more effective than either drug alone at the maximal tolerated dose.
uAm Coll CardioI1987;9:1369-74) effects of quinidine differ from those of tocainide, a combination of tocainide and quinidine in smaller and more tolerable doses may render additive antiarrhythmic effects without additive dose-related side effects . This was studied in 20 patients with coronary artery disease and frequent (2:30/h) ventricular premature complexe s.
Methods
Study design. All patients had coronary artery disease with frequent (2:30/h) ventricular premature complexes and were referred to the arrhythmia service of our medical center for recurrent sustained ventricular tachycardia (14 patients) or symptomatic ventricular arrhythmia (6 patients). No patient had uncompensated congestive heart failure at the time of entry into the study. There were 15 men and 5 women , aged 62 ± 10 years. At least five half-lives after all antiarrhythmic drugs were discontinued, a baseline 24 hour ambulatory electrocardiogram (ECG) was recorded in all patients .
Protocol. During single drug therapy with quinidine and tocainide, the initial dosage of quinidine (1,200 to 1,600 mg/day, given every 6 hours in equally divided doses) and tocainide (1,200 to 1,600 mg/day, given every 6 to 8 hours in equally divided doses) was adjusted to the maximal tolerated dosage without side effects. To alleviate side effects, tocainide was given with a snack (9) . A 24 hour ambulatory ECG recording was started when a patient had received quinidine at the maximal tolerated dosage for at least five doses and tocainide at the maximal tolerated dosage for at least 2 days to ensure steady state blood levels. During combination therapy with quinidine and tocainide, many patients received less of each drug, and none received more, than they received during single dose therapy. The dose adjustments during combination therapy were largely empiric and determined by the investigators on the basis of side effects, patients' body weight and frequency of ventricular premature complexes noted on the telemetry unit monitors. After combination therapy had been established for at least 2 days, another ambulatory ECG was recorded. The serum level of quinidine was obtained I hour before the next dose of quinidine during quinidine therapy and combination therapy. The serum concentration of tocainide was not determined because this assay was not available in our institution at the time of our study.
Ambulatory ECGs. Continuous 24 hour ambulatory
ECGs were recorded on an Avionics 445 two channel recorder. Analysis of the tape was performed on a computerized Cardio Data System scanner. Total numbers of ventricular premature complexes, couplets and ventricular tachycardia (;::::3 ventricular premature complexes at a rate > 100 beats/min) were generated by the scanner. The accuracy of this system has been published (II). Mean ventricular premature complexes or couplets/h were calculated by dividing the total number of ventricular premature complexes or couplets by the number of hours recorded. The results were verified by one of us.
Statistical methods. Standard deviation (mean ± SD)
was used as the index of dispersion of observed values. One-way analysis of variance (ANOYA), the Kruskal-Wallis test or Fisher's exact test was used to compare appropriate variables between groups. A two-tailed probability (p) value of <0.05 was considered significant.
Results
Antiarrhythmic therapy. During single drug therapy the dosage of tocainide was 1,680 ± 437 and that of quinidine was 1,340 ± 235 mg/day. The dosage of tocainide during combination therapy was 1,350 ± 394 mg/day and was significantly less than that during treatment with tocainide alone (p < 0.005). In 10 of the 20 patients, a lower dosage of tocainide was given during combination treatment. No patient received more tocainide during combination treatment. The dosage of quinidine during combination therapy was 1,060 ± 268 mg/day and was significantly less than that during treatment with quinidine alone (p < 0.01 versus single drug therapy). A lower dosage of quin- Numbers in parentheses are percent of baseline value in each patient. Combination = combination of quinidine and tocainide. Because of wide variation in frequency of ventricular ectopic activity among individual patients at baseline. the frequency of ventricular arrhythmias during each treatment period was also expressed as percent of the baseline value in each patient. Compared with the baseline value of each patient (I00%), the frequency of ventricularprematurecomplexes was reduced to 33 ± 44% with quinidine alone, 39 ± 30% with tocainide alone and 10 ± 16% with combination therapy (p < 0.001 for tocainide versus combination; 
Discussion
Our study suggests that in patients with coronary artery disease and frequent ventricular premature complexes 1) the antiarrhythmic effects of quinidine and tocainide are additive, and 2) a combination of quinidine and tocainide in smaller and well tolerated doses may avoid dose-related side p < 0.01 for quinidine versus combination; p = NS for quinidine versus tocainide). The frequency of couplets was reduced to 14 ± 24% with quinidine alone, 19 ± 34% with tocainide and 1.4 ± 3.9% with combination therapy (p < 0.05 for combination versus quinidine or tocainide alone; p = NS for quinidine versus tocainide). The frequency of nonsustained ventricular tachycardias was reduced to 15.6 ± 30.4% with tocainide, 10.8 ± 0.2% with quinidine and 0.16 ± 0.72% with combination therapy (p < 0.05 for tocainide versus combination; p = NS for quinidine versus combination and quinidine versus tocainide).
Ambulatory ECG: individual responses (Tables 1, 2  and 3) . A significant (>83%) reduction of ventricular premature complexes (12) was noted in 9 of the 20 patients on quinidine alone, 6 on tocainide alone and 16 on combination treatment (p < 0.005 for tocainide versus combination; p < 0.05 for quinidine versus combination; p = NS for tocainide versus quinidine). Abolition of nonsustained ventricular tachycardia (13) was noted in 10 patients (50%) on tocainide, 13 (65%) on quinidine and 19 (95%) during combination treatment (p < 0.005 for tocainide versus combination; p < 0.05 for quinidine versus combination; p = NS for tocainide versus quinidine). An effective regimen defined as a >83% reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia (13-15) was found in 3 patients (15%) on tocainide, 6 (30%) on quinidine and 16 (80%) on combination treatment (p < 0.005 for combination versus quinidine or tocainide alone; p = NS for quinidine versus tocainide).
Twelve lead ECG (Table 4 ). Significant prolongation of the QRS complex and QTc (corrected QT interval by the Bazett formula) (16) was noted during quinidine and combination therapy (p < 0.001). During tocainide therapy, no significant changes in duration of QRS complex and QTc interval were noted. The duration of QRS complexes and QTc interval during combination therapy were significantly shorter than those during quinidine alone (p < 0.05). effects and is more effective than either drug used alone at higher doses. Therefore, when quinidine or tocainide is ineffective because dose-related side effects limit the maximal tolerated dosage, combination therapy in smaller and more tolerable dosages may be more effective than either drug alone at maximal tolerated dosage.
Holter monitoring. A 24 hour ambulatory ECG was used to assess the antiarrhythmic efficacy of single drug and combination therapy in our study. Other investigators (1-3,5,13-15,17,18 ) have also used a 24 hour ambulatory ECG to assess efficacy of antiarrhythmic agents. Because of day to day variations in the frequency of ventricular premature complexes in individual patients, only a marked (>83%) reduction in ventricular premature complexes can be attributed to specific antiarrhythmic agents (12, 19) when comparing the results of one 24 hour ambulatory monitoring during each therapy. Michelson and Morganroth (20) also reported that a 75% reduction in the frequency of couplets and a 65% reduction in the frequency of nonsustained ventricular tachycardia would be required to demonstrate therapeutic efficacy. When evaluating antiarrhythmic agents in groups of patients, however, the spontaneous variability becomes less important and less dramatic reductions of ventricular ectopy are considered significant (19) . Therefore, comparing the results of a 24 hour ambulatory monitoring during each treatment period in a group of 20 patients, the day to day variations in ventricular premature complexes, couplets and nonsustained ventricular tachycardia in individual patients are not considered critical (19) . The combination therapy was more effective than single drug therapy with quinidine or tocainide when group responses as well as individual responses were considered.
Single drug therapy. In our study, a significant (>83%) reduction of ventricular premature complexes was noted in 30% of patients during tocainide therapy. This rate appears to be lower when compared with response rates of other studies. Winkle et al. (1) reported that ventricular premature complexes were suppressed by more than 70% in 11 (73%) of 15 patients. Woosley et al. (2) reported that 8 (67%) of 12 patients had >75% reduction of ventricular premature complexes. LeWinter et al. (3) reported that 5 (50%) of 10 patients had >80% reduction of ventricular premature complex frequency. When a >70% reduction is considered significant, 8 (40%) of 20 patients in our study had a significant reduction of ventricular premature complexes and our results are thus not significantly different from those of others (1-3) (p = NS by Fisher's exact test). The response of our patients to quinidine is similar to that reported by others (21) . When tocainide and quinidine were compared, quinidine appeared to be more effective in reducing ventricular premature complexes and nonsustained ventricular tachycardia. However, the differences between quinidine and tocainide were not statistically significant. This finding is similar to that of Morganroth et al. (10) . The daily doses of tocainide and quinidine in our study were similar to those of others (9, 10) . These findings suggest that our patient population and study methods were not significantly different from those of other studies (1-3,9, 10,21) .
Other investigators (9) administered a snack with tocainide, as we did, to avert dose-related side effects. By delaying absorption oftocainide, a snack could blunt a sharp increase in peak serum concentration without altering the total bioavailability (9) . In some patients, tocainide was given every 6 hours rather than every 8 hours to further minimize dose-related side effects. Other investigators (22) also used shorter dosing intervals to lessen dose-related side effects of mexiletine. By giving the same total daily dosage of a drug in smaller and more frequent doses, one may avoid the sharp increase in serum drug concentration and doserelated side effects seen after administrations of larger doses of the drug given at less frequent intervals.
Combination therapy. Tocainide and quinidine have different side effects (9-11). Therefore, combination of tocainide and quinidine may render additive antiarrhythmic effects without additive side effects. The results of our study support this assumption. The combination of different antiarrhythmic agents has been reported on by several investigators (11,18,22,23). Duff et al. (22) reported enhanced efficacy and reduction of dose-related side effects of mexiletine when combined with quinidine. Our results suggest that efficacy and tolerance of tocainide also improve when it is combined with quinidine. Although mexiletine and tocainide are congeners of lidocaine with similar electrophysiologic effects, Hession et al. (24) recently reported that the two agents have different clinical effects and each agent should be evaluated individually. No other investigators have studied the combination of tocainide and quinidine.
Duff et al. (22) reported that addition of mexiletine to quinidine shortens the quinidine-induced increase in QTc interval. In our study, the durations of the QRS complex and QTc interval during combination therapy were significantly shorter than those during quinidine alone. However, because the dosage of quinidine was less during combination therapy, one cannot determine from our study if tocainide has any influences on the quinidine-induced increase in QRS duration and QTc interval.
Clinical implications. A significant number of patients develop dose-related side effects from quinidine or tocainide administered in doses that achieve plasma levels adequate for arrhythmia suppressions (8, 22) . When the dose of the drug is reduced, the arrhythmias often recur (8) . Our study suggests that a combination of smaller and well tolerated dosages of quinidine and tocainide may be useful in such situations. Combination of the two agents in smaller doses, although they may be subtherapeutic when used individually, may render therapeutic effects.
When the maximal dosage of one agent (for example, 1,600 mg/day of quinidine or 2,400 mg/day of tocainide in our study) is well tolerated without side effects but is ineffective, further increase in the dose may cause adverse cardiac side effects such as an excessive prolongation of the QTc interval and torsade de pointes from quinidine (25) . In this situation, a combination of the maximal dosage of quinidine and the maximal or submaximal dosage of tocainide may be safer and more effective compared with giving more than the customarily used maximal dosage of quinidine. Others (26) have reported that a combination of the maximal dose of mexiletine and the maximal dose of quinidine is safe and effective. In our study, however, less quinidine and tocainide were used during the combination therapy. Therefore, the assumption regarding safety and efficacy of combining the two agents in the maximal dosage remains to be tested. Our patients had coronary artery disease and frequent (2':30/h) ventricular premature complexes. No patient had significant congestive heart failure before drug therapy. The results of our study may not be applicable to other patient groups. In addition, our study included acute drug testing using 24 hour Holter monitoring. Long-term follow-up studies will be necessary to determine the long-term effects of the combination therapy.
